Voices
Yüksel Ürün
Yüksel Ürün/X

Yüksel Ürün: High Response in cSCC but Significant Rejection Risk With Checkpoint Drugs

Yüksel Ürün, Medical Oncology Professor at Ankara University School of Medicine, shared a post on X about a paper by Armando Teixeira-Pinto et al. published in JAMA Oncology:

“In 343 solid organ transplant patients on checkpoint drugs:

  • Rejection 36% and graft loss 18% at 1 year.
  • Best ORR was skin cSCC: 61% response, better 1-year survival.
  • Steroid+mTOR had less rejection.”

Title: Outcomes of Solid Organ Transplant Recipients With Advanced Cancers Receiving Immune Checkpoint Inhibitors: A Systematic Review and Individual Participant Data Meta-Analysis

Authors: Armando Teixeira-Pinto, Jacqueline H. Stephens, Annabelle Wilson, Anh Kieu, Ryan P. Gately, Farzaneh Boroumand, Edmund Chung, Billie Bonevski, Matteo S. Carlino, Robert Carroll, Wai H. Lim, Jonathan C. Craig, Naoka Murakami, and Germaine Wong.

You can read the Full Article in JAMA Oncology.

Yüksel Ürün: High Response in cSCC but Significant Rejection Risk With Checkpoint Drugs

More posts featuring Yüksel Ürün.

Anh Kieu Annabelle Wilson Armando Teixeira-Pinto Billie Bonevski cancer Edmund Chung Farzaneh Boroumand Germaine Wong Jacqueline H. Stephens Jonathan C. Craig Matteo S Carlino Naoka Murakami OncoDaily Oncology Robert Carroll Ryan P. Gately Wai H. Lim Yüksel Ürün